Primary brain tumors are a diverse group of diseases that together constitute the most common solid tumor of childhood. The Central Brain Tumor Registry of the United States (CBTRUS) estimates that approximately 4,300 U.S. children are diagnosed each year.[1]
Brain tumors are classified by histology, but tumor location and extent of spread are also important factors that affect treatment and prognosis. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of proliferative activity are increasingly used in tumor diagnosis and classification.[2]
For information about the type of childhood brain and spinal cord tumor and its related PDQ summary, see the table below. If a tumor type is not listed, a corresponding PDQ treatment summary is not available.
| Tumor Type (Based on the 2021 WHO Classification)a | Pathological Subtype (Based on the 2021 WHO Classification)a | Related PDQ Treatment Summary |
|---|---|---|
| CNS = central nervous system; NEC = not elsewhere classified; NOS = not otherwise specified; WHO = World Health Organization. | ||
| aWHO classification adapted from Louis et al.[1] | ||
| Pediatric-type diffuse high-grade gliomas | Diffuse pediatric-type high-grade glioma, H3-wild type and IDH-wild type | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Diffuse midline glioma, H3 K27-altered | ||
| Diffuse hemispheric glioma, H3 G34-mutant | ||
| Infant-type hemispheric glioma | ||
| Circumscribed astrocytic gliomas | Pilocytic astrocytoma | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| High-grade astrocytoma with piloid features | ||
| Subependymal giant cell astrocytoma | ||
| Pleomorphic xanthoastrocytoma | ||
| Choroid glioma | ||
| Astroblastoma, MN1-altered | ||
| Ependymal tumors | Subependymoma | Childhood Ependymoma Treatment |
| Myxopapillary ependymoma | ||
| Supratentorial ependymoma, NOS | ||
| Supratentorial ependymoma, ZFTA fusion–positive | ||
| Supratentorial ependymoma, YAP1 fusion–positive | ||
| Posterior fossa ependymoma, NOS | ||
| Posterior fossa group A (PFA) ependymoma | ||
| Posterior fossa group B (PFB) ependymoma | ||
| Spinal ependymoma, NOS | ||
| Spinal ependymoma, MYCN-amplified | ||
| Pediatric-type diffuse low-grade glioma | Diffuse astrocytoma, MYB- or MYBL1-altered | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Angiocentric glioma | ||
| Polymorphous low-grade neuroepithelial tumor of the young | ||
| Diffuse low-grade glioma, MAPK pathway-altered | ||
| Glioneuronal and neuronal tumors | Dysembryoplastic neuroepithelial tumor | Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment |
| Ganglioglioma | ||
| Gangliocytoma | ||
| Desmoplastic infantile ganglioglioma | ||
| Desmoplastic infantile astrocytoma | ||
| Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (provisional entity) | ||
| Papillary glioneuronal tumor | ||
| Rosette-forming glioneuronal tumor | ||
| Myxoid glioneuronal tumor | ||
| Diffuse leptomeningeal glioneuronal tumor | ||
| Multinodular and vacuolating neuronal tumor | ||
| Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease) | ||
| Extraventricular neurocytoma | ||
| Cerebellar liponeurocytoma | ||
| Central neurocytoma | ||
| Tumors of the pineal region | Pineoblastoma | Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment |
| Embryonal tumors | Medulloblastoma, WNT-activated | Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment |
| Medulloblastoma, SHH-activated and TP53-mutant; Medulloblastoma, SHH-activated and TP53-wildtype | ||
| Medulloblastoma, non-WNT/non-SHH | ||
| Medulloblastoma, histologically defined | ||
| Desmoplastic nodular medulloblastoma | ||
| Medulloblastoma with extensive nodularity | ||
| Large cell medulloblastoma | ||
| Anaplastic medulloblastoma | ||
| Embryonal tumor with multilayered rosettes, C19MC-altered | ||
| CNS tumor with BCOR internal tandem duplication | ||
| CNS neuroblastoma, FOXR2-activated | ||
| CNS embryonal tumor, NEC/NOS | ||
| Atypical teratoid/rhabdoid tumor | Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment | |
| Germ cell tumors | Germinoma | Childhood Central Nervous System Germ Cell Tumors Treatment |
| Embryonal carcinoma | ||
| Yolk sac tumor | ||
| Choriocarcinoma | ||
| Mature teratoma | ||
| Immature teratoma | ||
| Teratoma with somatic-type malignancy | ||
| Mixed germ cell tumor | ||
| Tumors of the sellar region | Adamantinomatous craniopharyngioma | Childhood Craniopharyngioma Treatment |
| Papillary craniopharyngioma | ||
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This summary was comprehensively reviewed and extensively revised.
This summary was renamed from Childhood Brain and Spinal Cord Tumors Treatment Overview.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® Cancer Information for Health Professionals pages.
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood brain and spinal cord tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.
This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Childhood Brain and Spinal Cord Tumors Summary Index are:
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
The preferred citation for this PDQ summary is:
PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Brain and Spinal Cord Tumors Summary Index. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/brain/hp/child-brain-treatment-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389453]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.